BioMarin Pharma (BMRN) Tops Q1 EPS by 39c ; Offers Guidance
Tweet
Share
E-mail
Get Alerts BMRN Hot Sheet
Price: $55.90 +2.21%
Revenue Growth %: +13.2%
Financial Fact:
NET INCOME (LOSS) PER SHARE, BASIC: -0.26
Today's EPS Names:
OCCI, MAYS, CRMT, More
Revenue Growth %: +13.2%
Financial Fact:
NET INCOME (LOSS) PER SHARE, BASIC: -0.26
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q1 EPS of $0.71, $0.39 better than the analyst estimate of $0.32. Revenue for the quarter came in at $649 million versus the consensus estimate of $649.27 million.
GUIDANCE:
BioMarin Pharma sees FY2024 EPS of $2.75-$2.95, versus the consensus of $2.75. BioMarin Pharma sees FY2024 revenue of $2.7-2.8 billion, versus the consensus of $2.76 billion.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- H.C. Wainwright Reiterates Neutral Rating on BioMarin Pharmaceutical Inc. (BMRN)
- C.H. Robinson acquires DeSpir Logistics for $75 million
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
